Compare YieldMax AI & Tech Portfolio Option Income ETF (GPTY) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
YieldMax AI & Tech Portfolio Option Income ETF vs Novo Nordisk A/S — how do they compare? YieldMax AI & Tech Portfolio Option Income ETF trades at $43.11, while Novo Nordisk A/S trades at $46.5 (market cap $207.85B). The key difference: Novo Nordisk A/S pays a 3.81% dividend while YieldMax AI & Tech Portfolio Option Income ETF pays none, and YieldMax AI & Tech Portfolio Option Income ETF is trading nearer its 52-week high, Novo Nordisk A/S nearer its low. Which is the better fit depends on your goals.
| GPTY | NVO | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $50.52 | $63.98 |
52-Week Low | $34.73 | $35.29 |
Market Cap | — | $207.85B |
Enterprise Value | — | $222.55B |
Dividend Yield | — | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GPTY trades at $42.99, up 0.79% on the day, with a bullish technical signal from moving averages and ADX indicators, though RSI_6 at 83.06 suggests overbought conditions. The ETF maintains a consistent weekly dividend distribution strategy, with recent payouts ranging from $0.28 to $0.38, highlighting its income-focused approach through option premiums on AI and tech equities.
Outlook remains positive due to strong AI theme exposure and income generation, but risks include reliance on semiconductor momentum and potential NAV erosion from option strategies. Investors benefit from high yield but face volatility tied to tech sector performance.
Novo Nordisk (NVO) trades at $46.465, down 2.65% today, with a neutral technical signal. The stock shows strong fundamentals, including a P/E of 11.62, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights competitive pressures from Eli Lilly and mixed investor reactions to Q2 2026 results, despite an upwardly revised full-year outlook.
Outlook remains positive due to robust GLP-1 drug demand and profitability, but risks include pricing pressure and competition. Analysts are predominantly bullish (57.9% buy ratings), supporting a favorable long-term view despite near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About YieldMax AI & Tech Portfolio Option Income ETF
GPTY is an actively managed ETF that seeks to provide current income and capital appreciation by holding a concentrated portfolio of 15 to 30 leading AI and technology companies. It utilizes a variety of options strategies, including selling call options on its underlying holdings, to generate weekly distributions while maintaining direct equity exposure to the growth of the AI sector.
Read more on GPTY →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
